finding,pubmed_id,finding_id
A heterologous vsv- and ad5-vectored vaccine developed and produced at the Gamaleya Research Center for Epidemiology and Microbiology is currently the only licensed vaccine for Ebola fever.,PMC5662269,PMC5662269_0
A recombinant human adenovirus serotype 5 (Ad5)-based vaccine encoding full-length 2014 Zebra Ebola glycoprotein (GP) passed phase 1 clinical trials in China and progressed to phases 2 and 3.,PMC5662269,PMC5662269_1
"A recombinant human adenovirus serotype 26 or adenovirus chimpanzee serotype 3 (Ad3)-based vaccine passed phase 1 clinical trials and demonstrated 100% short-term protection (5 weeks) after boosting, but protection decreased to 33% in 8 months.",PMC5662269,PMC5662269_2
A recombinant human adenovirus serotype 5 (Ad5)-based vaccine encoding full-length 2014 Zebra Ebola GP and a recombinant human adenovirus serotype 5 (Ad5)-based vaccine encoding full-length 1976 Mayinga Ebola GP passed phase 1 clinical trials in the United States.,PMC5662269,PMC5662269_3
A series of preclinical trials in primates demonstrated that immunization with a heterologous vsv- and ad5-based vaccine for Ebola fever provides 100% protection from infection to animals both 3 weeks and 5 months after immunization.,PMC5662269,PMC5662269_4
